Combined effects of probucol and bezafibrate on lipoprotein metabolism and liver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits

Japanese Circulation Journal

Volumn 63, Issue 6, 1999, Pages 471-477

  Ou, Jiafu ^a   Saku, Keijiro ^a   Jimi, Shiro ^a   Liao, Yuan Lan ^a   Ohta, Takao ^b   Zhang, Bo ^a   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Bezafibrate; Cholesteryl ester transfer protein; Hypercholesterolemia; Lipids; Lipoproteins; mRNA; Probucol

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PROBUCOL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG BLOOD LEVEL; HYPERCHOLESTEROLEMIA; LIPOPROTEIN METABOLISM; LIVER; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; BASE SEQUENCE; BEZAFIBRATE; BLOTTING, NORTHERN; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLYCOPROTEINS; LIPIDS; LIPOPROTEINS; LIVER; MALE; MOLECULAR SEQUENCE DATA; PROBUCOL; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0033018781     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.63.471     Document Type: Article

References (39)

1. Carew TE, Schwenke GC, Steinberg D: Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987; 84: 7725-7729
2. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, et al: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987; 84: 5928-5931
3. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonnico L, Chiesa G, et al: Mechanisms of HDL reduction after probucol: Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arterioscler Thromb 1989; 9: 462-469
4. McPherson R, Hogue M, Milne RW, Tall AR, Marcel YL: Increase in plasma cholesteryl ester transfer protein during probucol treatment: Relation to changes in high density lipoprotein composition. Arterioscler Thromb 1991; 11: 476-481
5. Yamamoto A, Matsuzawa Y, Yokayama S, Funahachi T, Yamamura T, Kishino B: Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986; 57: 29H-35H
6. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, et al: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365-372
7. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, et al: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997; 30: 855-862
8. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, et al: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74: 875-883
9. Saku K, Sasaki J, Arakawa K: Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia. Clin Ther 1989; 11: 331-340
10. Stewart JM, Packard CJ, Lorimer AR, Boag DE, Shepherd J: Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis 1982; 44: 355-365
11. Vessby B, Lithell H, Ledermann H: Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate. Atherosclerosis 1982; 44: 113-118
12. de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A: Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther 1997; 11(Suppl 1): 257-263
13. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-853
14. Liu R, Saku K, Jimi S, Ohta T, Zhang B, Takebayashi S, et al: Mechanism of action of gemfibrozil on HDL metabolism and atherosclerosis in WHHL rabbits. Cardiovasc Drugs Ther 1997; 11: 659-668
15. Saitoh K, Mori T, Kasai H, Nagayama T, Tsuchiya A, Ohbayashi S: Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromalous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits. Folia Pharmacol Jpn 1995; 106: 41-50
16. Davignon J: Medical management of hyperlipidemia and the role of probucol. Am J Cardiol 1986; 57: 22H-28H
17. Witstum JL, Simmons D, Steinberg D, Beltz WF, Weinreb R, Young SG, et al: Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation 1989; 79: 16-28
18. Illingworth DR, Bacon S: Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arteriosclerosis 1989; 9: 121-134
19. Saku K, Zhang B, Hirata K, Okura Y, Bai H, Liu R, et al: Combined therapy with probucol and pravastatin in hypercholesterolemia. Eur J Clin Pharmacol 1993; 44: 535-539
20. Saku K, Zhang B, Jimi S, Bai H, Hirata K, Sasaki N, et al: Highdensity lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate. Eur J Clin Pharmacol 1995; 48: 209-215
21. Yokoyama S, Yamamoto A, Kurasawa T: A little more information about aggravation of probucol-induced HDL-reduction by clofibrate. Atherosclerosis 1988; 70: 179-181
22. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353
23. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-475
24. Eggstein M, Kreutz FH: Eine neue Bestimmung der Neutralfette in Blutserum und Gewebe. I. Mit Prinzip, Durchfuhrung und Besprechung des Methiode. Klin Wochenschr 1966; 44: 262
25. Kato H, Nakanishi T, Arai H, Nishida HI, Nishida T: Purification, microheterogeneity, and stability of human lipid transfer protein. J Biol Chem 1989; 264: 4082-4087
26. Hayashibe H, Asayama K, Nakane T, Uchida N, Kawada Y, Nakazawa S: Increased plasma cholesteryl ester transfer activity in obese children. Atherosclerosis 1997; 129: 53-58
27. Nagano Y, Kita T, Yokode M, Ishii K, Kume N, Otani H, et al: Probucol does not affect lipoprotein metabolism in macrophages of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis 1989; 9: 453-461
28. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory Press, 1989
29. Ying H, Saku K, Harada R, Takami N, Sasaki N, Saito Y, et al: Putative mechanisms of action of probucol on high-density lipoprotein apolipoproteinA-I and its isoprotein kinetics in rabbits. Biochim Biophys Acta 1990; 1047: 247-254
30. Nestel PJ, Billington T: Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis 1981; 38: 203-209
31. Atmeh RF, Stewart JM, Boag DE, Packard CJ, Lorimer AR, Shepherd J: The hypolipidemic action of probucol: a study of its effect on high and low density lipoproteins. J Lipid Res 1983; 24: 588-595
32. Saku K, Gartside P, Hynd BA, Kashyap ML: Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985; 75: 1702-1712
33. Tsujita M, Yokoyama S: Selective inhibition of free apolipoproteinmediated cellular lipid efflux by probucol. Biochemistry 1996; 35: 13011-13020
34. Quinet EM, Huerta P, Nancoo D, Tall AR, Marcel YL, McPherson R: Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence. J Lipid Res 1993; 34: 845-852
35. Saku K, Zhang B, Ohta T, Liu R, Jimi S, Shirai K, et al: Quantity and function of high density lipoprotein as an indicator of coronay atherosclerosis. J Am Coll Cardiol 1999: (in press)
36. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Mikami Y, et al: Effect of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 1994; 106: 191-201
37. Quinet EM, Agellon LB, Kroon PA, Marcel YL, Lee YC, Whitlock ME, et al: Atherogenic diet increases cholesteryl ester transfer protein messenger RNA levels in rabbit liver. J Clin Invest 1990; 85: 357-363
38. Ou J, Saku K, Jimi S, Ohta T, Zhang B, Pownall HJ, et al: Mechanism of action of probucol cholesterol ester transfer protein (CETP) mRNA in a Chinese hamster ovary cell line that had been stably transfected with a human CETP gene. Biochim Biophys Acta 1998; 1393: 153-160
39. Nagashima M, McLean JW, Lawn RM: Cloning and mRNA tissue distribution of rabbit cholesteryl ester transfer protein. J Lipid Res 1988; 29: 1643-1649